Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients

2013 ◽  
Vol 48 (10) ◽  
pp. 1188-1204 ◽  
Author(s):  
Masataka Tsuge ◽  
Eisuke Murakami ◽  
Michio Imamura ◽  
Hiromi Abe ◽  
Daiki Miki ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Nucleotide Analogue ◽  
Safe Discontinuation

Interferon versus direct antiviral therapy in patients with chronic hepatitis B

2011 ◽  
Vol 152 (22) ◽  
pp. 869-874 ◽  
Author(s):  
István Tornai
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Pegylated Interferon ◽  
Antiviral Effect ◽  
Interferon Alfa ◽  
First Line ◽  
Nucleotide Analogue ◽  
Pegylated Interferon Alfa

Treatment of chronic hepatitis B is still challenging. Lots of parameters are needed to be considered before and during the therapy. There are several possible endpoints and their durability is very much variable. Patients with HBeAg-positive and HBeAg-negative hepatitis B need treatment. Two different strategies are available. Interferon-based therapy is a limited treatment, which might result in a sustained immune response in about one third of the patients, leading to an induced remission, sometimes years after the end of the treatment. According to the other strategy a continuous, indefinite oral nucleoside/nucleotide analogue (NA) treatment is administered to maintain a remission. However, relapse is rather frequent after the cessation of this therapy. During the long-term NA treatment drug resistance can lead to the loss of antiviral effect. Three first-line drugs are recommended, pegylated interferon alfa-2a, entecavir and tenofovir. If there is no contraindication to interferon, it is worth trying to achieve immune control and an induced remission. In patients, who do not respond to interferon, a sequential NA therapy is indicated. Orv. Hetil., 2011, 152, 869–874.

scholarly journals Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Abhasnee Sobhonslidsuk ◽  
Pawin Numthavaj ◽  
Jirachaya Wanichanuwat ◽  
Areepan Sophonsritsuk ◽  
Supanna Petraksa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Fractional Excretion ◽  
Tubular Dysfunction ◽  
Renal Tubular Dysfunction ◽  
Nucleotide Analogue ◽  
Proximal Renal Tubular Dysfunction ◽  
Renal Tubular ◽  
One Year

Aims. Proximal renal tubular dysfunction (PRTD) is an infrequent complication after nucleotide analogue therapy. We evaluated the outcomes of PRTD and nephrotoxicity after nucleotide analogue withdrawal in chronic hepatitis B (CHB). Methods. A longitudinal follow-up study was performed in patients with PRTD after nucleotide analogue discontinuation. Serum and urine were collected at baseline and every 3 months for one year. The fractional excretion of phosphate (PO4), uric acid (UA), and potassium and tubular maximal reabsorption rate of PO4 to glomerular filtration rate (TmPO4/GFR) were calculated. Renal losses were defined based on the criteria of substance losses. Subclinical PRTD and overt PRTD were diagnosed when 2 and ≥3 criteria were identified. Results. Eight subclinical and eight overt PRTD patients were enrolled. After nucleotide analogue withdrawal, there were overall improvements in GFR, serum PO4, and UA. Renal loss of PO4, UA, protein, and β2-microglobulin reduced over time. At one year, complete reversal of PRTD was seen in 13 patients (81.2%). Improvements in PRTD were seen in all but one patient. Conclusion. One year after nucleotide analogue withdrawal, PRTD was resolved in most patients. Changes in TmPO4/GFR, urinary protein, and β2-microglobulin indicate that urinary biomarkers may represent an early sign of PRTD recovery.

scholarly journals Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B

Gut and Liver ◽  
2020 ◽  
Vol 14 (2) ◽  
pp. 225-231
Author(s):  
Young Youn Cho ◽  
Young Chang ◽  
Joon Yeul Nam ◽  
Hyeki Cho ◽  
Eun Ju Cho ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Nucleotide Analogue
Sign in / Sign up

Export Citation Format

Share Document